
Coloplast A/S - Q1 2024/25 Earnings Release - Invitation To Conference Call On 4 February 2025 At 11.00Am CET
In connection with the publication of Coloplast's interim financial results for Q1 2024/25, to be released same day around CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast's website approximately 1 hour before the conference call.
The webcast of the conference call will be available during and after the event.
Coloplast will be represented by:
Kristian Villumsen - President & CEO
Anders Lonning-Skovgaard - Executive Vice President, CFO
Aleksandra Dimovska - Vice President, Investor Relations
Simone Dyrby Helvind - Senior Manager, Investor Relations
Webcast
For participants who do not wish to actively participate in the Q&A session, please access the conference call as a webcast via the link below:
Access the webcast here
Dial-in details
To actively participate in the Q&A session, please sign up ahead of the conference call on the link below to receive an email with dial-in details.
Register for the conference call here
For more information, please contact:
Aleksandra Dimovska - Vice President, Investor Relations
Tel.: +45 4911 1800 / direct: +45 4911 2458. E-mail: ...
Simone Dyrby Helvind - Senior Manager, Investor Relations
Tel.: +45 4911 1800 / direct: +45 4911 2981. E-mail: ...
Julie Isabella Sommer Müggler - Coordinator & PA, Investor Relations
Tel.: +45 4911 1800 / direct: +45 4911 3161. E-mail: ...
Coloplast will be available on individual phone lines after the conference call for further questions.
Attachment
- Invitation for Coloplasts Q1 2024-25 conference call on 4 february 2025


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Comments
No comment